Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma.

Cancers (Basel) · 2021 · PMC8431561 · PMID 34503232

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Combined therapy with crizotinib+decitabine or crizotinib+trametinib resulted in a significantly higher inhibition of tumor growth compared to single treatments, while tumors treated with crizotinib+CHO showed a trend toward better inhibition compared to single drugs ( Figure 3 E). 3.4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.